3 completed, 3 withdrawn, 2 terminated, 1 recruiting. 10 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Withdrawn 3, Terminated 2, Recruiting 1, Suspended 1 |
| Phase 1 | 2 | Completed 1, Suspended 1 |
Follow brincidofovir: new trials by email Literature Review of brincidofovir trials Research Report on brincidofovir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study Brincidofovir - Progressive Multifocal Leukoencephalopathy | Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 24 | 2026-06-05 | 2026-07-22 |
| A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Brincidofovir - Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | Suspended | SymBio Pharmaceuticals | 43 | 2025-06-09 | 2026-02-05 |
| Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation Brincidofovir - BK Virus Infection, Nephropathy | Phase 2 | Terminated | SymBio Pharmaceuticals | 1 | 2022-10-14 | 2024-12-04 |
| Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia Brincidofovir, Standard of Care - Adenovirus | Phase 2 | Withdrawn | Jazz Pharmaceuticals | 2018-12-15 | 2021-07-21 | |
| The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation Standard of Care, Brincidofovir - Adenovirus | Phase 2 | Terminated | Jazz Pharmaceuticals | 29 | 2017-12-22 | 2021-01-25 |
| An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease CMX001 - Ebola Virus | Phase 2 | Withdrawn | Jazz Pharmaceuticals | 2014-10-01 | 2015-02-02 | |
| An Open-Label Study , Safety and Tolerability of Brincidofovir for Post Exposure Prophylaxis of Ebola Brincidofovir - Ebola Virus Disease | Phase 2 | Withdrawn | Jazz Pharmaceuticals | 2014-10-01 | 2020-02-26 | |
| Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease Brincidofovir, Placebo - Adenovirus Disease | Phase 2 | Completed | Jazz Pharmaceuticals | 52 | 2010-11-01 | 2021-07-21 |
| CMX001 in Post-transplant Patients With BK Virus Viruria Placebo, Brincidofovir - Viruria | Phase 1 / Phase 2 | Completed | Jazz Pharmaceuticals | 29 | 2009-11-01 | 2021-08-16 |
| Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Brincidofovir, Placebo - Cytomegalovirus Infection | Phase 2 | Completed | Jazz Pharmaceuticals | 239 | 2009-10-01 | 2021-07-16 |
Adenoviridae Infections (2) · Cytomegalovirus Infections (1) · Epstein-Barr Virus Infections (1) · Hemorrhagic Fever, Ebola (1) · Immunoblastic Lymphadenopathy (1) · Kidney Diseases (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Leukoencephalopathy, Progressive Multifocal (1) · Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, T-Cell (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Jazz Pharmaceuticals (7) · SymBio Pharmaceuticals (2) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (6) · Italy (2) · Japan (2) · Spain (2) · China (1) · France (1) · Germany (1) · Ireland (1) · Netherlands (1) · Poland (1) · Singapore (1) · United Kingdom (1)
PMID 27851688, PMID 24066743, PMID 28063938, PMID 39382091, PMID 40828617